173 related articles for article (PubMed ID: 31192894)
1. Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.
Mehrotra ML; Westreich D; McMahan VM; Glymour MM; Geng E; Grant RM; Glidden DV
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):e94-e98. PubMed ID: 31192894
[No Abstract] [Full Text] [Related]
2. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
[TBL] [Abstract][Full Text] [Related]
3. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
4. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
Jotwani V; Scherzer R; Glidden DV; Mehrotra M; Defechereux P; Liu A; Gandhi M; Bennett M; Coca SG; Parikh CR; Grant RM; Shlipak MG
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):169-174. PubMed ID: 29767638
[TBL] [Abstract][Full Text] [Related]
5. Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).
Defechereux PA; Mehrotra M; Liu AY; McMahan VM; Glidden DV; Mayer KH; Vargas L; Amico KR; Chodacki P; Fernandez T; Avelino-Silva VI; Burns D; Grant RM;
AIDS Behav; 2016 Jul; 20(7):1478-88. PubMed ID: 26078115
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
Kasonde M; Niska RW; Rose C; Henderson FL; Segolodi TM; Turner K; Smith DK; Thigpen MC; Paxton LA
PLoS One; 2014; 9(3):e90111. PubMed ID: 24625530
[TBL] [Abstract][Full Text] [Related]
8. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Solomon MM; Mayer KH; Glidden DV; Liu AY; McMahan VM; Guanira JV; Chariyalertsak S; Fernandez T; Grant RM;
Clin Infect Dis; 2014 Oct; 59(7):1020-6. PubMed ID: 24928295
[TBL] [Abstract][Full Text] [Related]
9. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
10. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.
Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz RJ; Reirden D; Malhotra M; Glenny C; Harding P; Powell T; Anderson PL; Hosek S
AIDS Res Hum Retroviruses; 2022 Dec; 38(12):939-943. PubMed ID: 35815468
[TBL] [Abstract][Full Text] [Related]
11. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
Carballo-Diéguez A; Giguere R; Dolezal C; Leu CS; Balán IC; Brown W; Rael C; Richardson BA; Piper JM; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla CD; Lama JR; McGowan I; Cranston RD;
AIDS Behav; 2017 Dec; 21(12):3336-3345. PubMed ID: 29119473
[TBL] [Abstract][Full Text] [Related]
12. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
13. Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities.
Restar AJ; Kuhns L; Reisner SL; Ogunbajo A; Garofalo R; Mimiaga MJ
AIDS Behav; 2018 Nov; 22(11):3649-3657. PubMed ID: 29713838
[TBL] [Abstract][Full Text] [Related]
14. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
Landovitz RJ; Donnell D; Clement ME; Hanscom B; Cottle L; Coelho L; Cabello R; Chariyalertsak S; Dunne EF; Frank I; Gallardo-Cartagena JA; Gaur AH; Gonzales P; Tran HV; Hinojosa JC; Kallas EG; Kelley CF; Losso MH; Madruga JV; Middelkoop K; Phanuphak N; Santos B; Sued O; Valencia Huamaní J; Overton ET; Swaminathan S; Del Rio C; Gulick RM; Richardson P; Sullivan P; Piwowar-Manning E; Marzinke M; Hendrix C; Li M; Wang Z; Marrazzo J; Daar E; Asmelash A; Brown TT; Anderson P; Eshleman SH; Bryan M; Blanchette C; Lucas J; Psaros C; Safren S; Sugarman J; Scott H; Eron JJ; Fields SD; Sista ND; Gomez-Feliciano K; Jennings A; Kofron RM; Holtz TH; Shin K; Rooney JF; Smith KY; Spreen W; Margolis D; Rinehart A; Adeyeye A; Cohen MS; McCauley M; Grinsztejn B;
N Engl J Med; 2021 Aug; 385(7):595-608. PubMed ID: 34379922
[TBL] [Abstract][Full Text] [Related]
15. Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
van Epps P; Maier M; Lund B; Howren MB; Beck B; Beste L; Skolnik A; Vaughan-Sarrazin M; Ohl ME
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):272-278. PubMed ID: 29210835
[TBL] [Abstract][Full Text] [Related]
16. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
[TBL] [Abstract][Full Text] [Related]
17. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE
AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
20. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
